Deep Shah

Dr. Deep Shah

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2018 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
SMS Shahzad Mustafa
S Shahzad Mustafa
DSDeep Shah
Deep Shah
JBJonathan Bress
Jonathan Bress
SJSaad Jamshed
Saad Jamshed
Infections are a major cause of morbidity and mortality in individuals with multiple myeloma (MM). These individuals exhibit humoral dysfunction and show a suboptimal response to pneumococcal polysaccharide vaccine (PPV23). Since pneumococcal conjugate vaccine (PCV13) elicits a T cell dependent response, it is recommended in patients with multiple myeloma. This study compares the initial response to PCV13 and durability of the response at 6 months in patients with multiple myeloma versus normal controls. Seven patients with multiple myeloma and 18 control patients were enrolled in the study. Streptococcal pneumonia serotype IgG titers were drawn at baseline, day 30, and day 180 after MM patients and controls received PCV13. Although vaccination with PCV13 produced a similar initial response in patients with multiple myeloma compared to control subjects, the duration of response may have waned in patients with multiple myeloma as compared to control subjects.

24 April 2023 in Hematology Reports
Verified
Journal Article
Open access
PDF file
SSShivani Shah
Shivani Shah
RSRyan Sweeney
Ryan Sweeney
MRMaitreyee Rai
Maitreyee Rai
DSDeep Shah
Deep Shah
A male in his 60s presented with left lower extremity fractures following a vehicle accident. Hemoglobin, initially, was 12.4 mmol/L, and platelet count was 235 k/mcl. On day 11 of admission, his platelet count initially dropped to 99 k/mcl, and after recovery it rapidly decreased to 11 k/mcl on day 16 when the INR was 1.3 and aPTT was 32 s, and he continued to have a stable anemia throughout admission. There was no response in platelet count post-transfusion of four units of platelets. Hematology initially evaluated the patient for disseminated intravascular coagulation, heparin-induced thrombocytopenia (anti-PF4 antibody was 0.19), and thrombotic thrombocytopenic purpura (PLASMIC score of 4). Vancomycin was administered on days 1–7 for broad spectrum antimicrobial coverage and day 10, again, for concerns of sepsis. Given the temporal association of thrombocytopenia and vancomycin administration, a diagnosis of vancomycin-induced immune thrombocytopenia was established. Vancomycin was discontinued, and 2 doses of 1000 mg/kg of intravenous immunoglobulin 24 h apart were administered with the subsequent resolution of thrombocytopenia.

16 November 2021 in Research and Practice in Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
MLMegan Langer
Megan Langer
MMMeredith Manire
Meredith Manire
MCMatthew Clarkson
Matthew Clarkson
YSYazan Samhouri
Yazan Samhouri
DSDeep Shah
Deep Shah
RBRama Bhagavatula
Rama Bhagavatula
Afibrinogenemia and congenital dysfibrinogenemia (CD) are rare conditions with limited information available for appropriate management. Previous case reports have demonstrated the safe and efficacious use of fibrinogen replacement therapy (FRT) as a therapeutic approach to prevent hemorrhage and fetal loss in pregnant women with CD. In this case report, we present a 28-year-old pregnant woman who sought testing for CD given her family history. She denied any current or previous bleeding symptoms. Laboratory testing confirmed the diagnosis of CD. She was treated with FRT and prophylactic anticoagulation starting in her third trimester. She had preterm labor that prompted an urgent cesarean section with FRT support. This case adds to the sparse literature about fibrinogen disorders in pregnancy, and highlights the benefits, safety, and tolerability of FRT and prophylactic anticoagulation in pregnant women with CD. Finally, it emphasizes the importance of a multidisciplinary team approach for an uneventful delivery.

9 May 2024 in Hematology Reports
Verified
Journal Article
Open access
PDF file
AAAbraham Attah
Abraham Attah
CPChelsea Peterson
Chelsea Peterson
MJMax Jacobs
Max Jacobs
RBRama Bhagavatula
Rama Bhagavatula
DSDeep Shah
Deep Shah
YSYazan Samhouri
Yazan Samhouri
Heparin products are frequently used in the inpatient setting to prevent and treat venous thromboembolism, but they simultaneously put patients at risk of developing heparin-induced thrombocytopenia (HIT). The 4Ts score determines the pretest probability of HIT. Diagnosis is made with a screening antiplatelet factor (PF4) immunoassay and the serotonin-release assay (SRA) as a confirmatory test. Anti-PF4 assays have high sensitivity (98%) but lower specificity (50%) and result in frequent false-positive tests. We present a rare case from our institution of a patient with anti-PF4–Polyanion ELISA-negative, SRA-positive HIT and describe the challenges in making a timely diagnosis in this case.

30 January 2021 in Cureus
Verified
Journal Article
Open access
PDF file
KSKarthik Shankar
Karthik Shankar
DSDeep Shah
Deep Shah
DHDeanna L. Huffman
Deanna L. Huffman
CPChelsea Peterson
Chelsea Peterson
RBRama Bhagavatula
Rama Bhagavatula
Sickle cell anemia patients often present to the hospital with acute vaso-occlusive pain crisis. Symptoms can include, but are not limited to, chest pain, abdominal pain, and musculoskeletal pain. These symptoms are brought about due to the pathology of the disease. Abnormal hemoglobin S causes red blood cells to band together, otherwise known as "sickling." These patients also often present with very low hemoglobin levels on initial evaluation. In most cases, packed red blood cell transfusions are needed in order to replenish these patient's functional hemoglobin supply. Unfortunately, transfusing sickle cell patients can lead to an unwanted consequence, that of hyperhemolysis syndrome, in which blood transfusions prompt further hemolysis of the already sickled red blood cells. When this complication arises, caution must be exercised in deciding the next steps of treatment.

8 June 2018 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
DSDeep Shah
Deep Shah
NKNida Khalid
Nida Khalid
This is a case of a young 34-year-old man who had symptomatic hyperthyroidism from an extremely high serum beta HCG level in the setting of a metastatic stage IIIC mixed germ cell tumour. The patient’s thyroid function normalised with treatment of the cancer as the beta HCG levels declined.